First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Autor: Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M.A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A.K., Fujimoto, N., Tsao, A.S., Mansfield, A.S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G.

Publikováno v: Annals of Oncology
Annals of Oncology, 2022, 33 (5), pp.488-499. ⟨10.1016/j.annonc.2022.01.074⟩
Annals of Oncology, 33(5), 488-499. ELSEVIER
Annals of Oncology, 33(5), 488-499. Elsevier Ltd.

International audience; Background: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4255710dc1654fd9d6b202fe1d21a85
https://doi.org/10.1016/j.annonc.2022.01.074

1915P Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma

Autor: Ning, M.S., Gandhi, S., Gomez, D.R., Chang, J.Y., Blumenschein, G., Rice, D., O'Reilly, M., Sepesi, B., Lin, S.H.H., Liao, Z., Le, X., Byers, L.A., Mehran, R., Hofstetter, W., Hernandez, M., Chen, Y-S., Jeter, M., Tsao, A.S.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S1115-S1115

Search committee diversity and applicant pool representation of women and underrepresented minorities : a quasi-experimental field study

Autor: Kazmi, M.A., Spitzmueller, C., Yu, J., Madera, J.M., Tsao, A.S., Dawson, J.F., Pavlidis, I.

The diversification of applicant pools constitutes an important step for broadening the participation of women and underrepresented minorities (URMs) in the workforce. The current study focuses on recruiting diverse applicant pools in an academic set

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::bfc78501ba750af5c498bca07532306a

EP14.03-05 Implant Associated Squamous Cell Carcinoma: An Emerging Chest Wall Malignancy.

Autor: Clemens, M.W., Fracol, M., Rodriguez, M.M., Tsao, A.S.

Publikováno v: Journal of Thoracic Oncology; 2023 Supplement, Vol. 18 Issue 11, pS722-S723, 2p

LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Autor: Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M.A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A.K., Fujimoto, N., Tsao, A.S., Mansfield, A.S., Popat, S., Zhang, X., Hu, N., Balli, D., Sanzari, J., Zalcman, G.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S1341-S1342